CloudBlue and CloudSense Strike a Strategic Relationship to Connect Telecommunications Providers With a Broad Ecosystem of ICT Channel Partners via a New Digital Catalog
5.4.2022 16:00:00 EEST | Business Wire | Press release
CloudBlue, a leading cloud ecosystem technology company which powers some of the largest commerce platforms for cloud and IT channel products globally, today announced an agreement with CloudSense, provider of one of the market’s most powerful Configure, Price, Quote (CPQ) platforms.
CloudSense has a well-established footprint within the telecommunications industry, with customers including prominent regional and international brands such as BT, Starhub and Vodafone Ziggo. By providing a direct integration from CloudBlue Connect™ to the CloudSense CPQ platform, CloudSense’s community of telecommunications customers will be able to tap into a new pool of ICT offerings and scale their business faster than ever.
The direct integration between CloudBlue Connect and CloudSense CPQ will allow telecommunications providers to enrich their own portfolio of B2B solutions more efficiently. This new integration will streamline their ability to procure traditional ICT services and bundle them into a wide range of innovative B2B XaaS solutions, which can be sold by a direct sales force or a network of resellers. Telecommunications and ICT providers will be able to create simple and easy quotes and contracts via CloudSense CPQ without the need to rekey orders or engage in manual processes.
CloudBlue will benefit from this new relationship through expanded exposure of its 200+ XaaS digital solutions to the telecommunications community. The initiative clears the way for CloudSense’s customers to access the tools they need to provide businesses of all sizes with the anything-as-a-service (XaaS) offerings that have surged in demand post-pandemic.
“As telcos look for new ways to diversify their offerings, cross-platform integration becomes key to providing end-users the best in Cloud. CloudBlue’s new agreement with CloudSense marks the latest in a series of innovative and creative relationships forming across Cloud to the continued delight of channel partners,” said Tarik Faouzi, senior vice president of CloudBlue.
“CloudSense recognizes the importance of bringing to market innovative solutions that address challenges in our focus verticals. We believe the CloudSense-CloudBlue agreement establishes the first Marketplace of its kind to facilitate commercial innovation across the communications ecosystem. This will give communications service providers broader access to a global network of channel partners and remove the need for manual input when drafting quotes and contracts,” said Jonathan English, CEO, CloudSense.
About CloudSense
The CloudSense Configure, Price, Quote (CPQ) application suite powers increased productivity and profits for ambitious enterprises allowing them to launch faster, sell more and fulfill orders faultlessly. Its growing global community of customers rely on CloudSense to deliver sales transformation within the Communications and Media industries. Leading brands including Telefonica, Telstra, and Informa use CloudSense's portfolio of applications to streamline the entire customer lifecycle, providing a better customer experience while improving business performance. To find out more, visit CloudSense.com
About CloudBlue
CloudBlue helps businesses succeed in the as-a-service economy and accelerate time to revenue by managing subscription and billing, vendor and product information, and partner onboarding across multiple channels. Through its leading ecosystem orchestration platform, CloudBlue enables companies to create their own ecosystems, as well as connect vendor and go-to-market ecosystems, automating the distribution of traditional and digital products and services across partners in the digital supply chain. CloudBlue serves more than 180 companies around the globe and powers the world’s largest cloud B2B marketplaces, which represent 30 million B2B cloud subscriptions. Learn more about CloudBlue at www.cloudblue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005045/en/
Contact information
Andrew Zelinko
CloudBlue
Andrew.Zelinko@cloudblue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off
PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release
Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N
AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 09:00:00 EEST | Press release
AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To
Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release
Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/ Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom